Insider Selling: LifeStance Health Group (NASDAQ:LFST) Director Sells $558,206.30 in Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) Director Robert Bessler sold 79,630 shares of the firm’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $7.01, for a total value of $558,206.30. Following the completion of the transaction, the director owned 1,382,175 shares in the company, valued at approximately $9,689,046.75. This trade represents a 5.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Robert Bessler also recently made the following trade(s):

• On Monday, December 15th, Robert Bessler sold 12,371 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.00, for a total transaction of $86,597.00.

LifeStance Health Group Trading Up 0.4%

NASDAQ LFST opened at $6.94 on Friday. The firm has a market capitalization of $2.70 billion, a price-to-earnings ratio of -231.33 and a beta of 1.13. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.58 and a current ratio of 1.58. LifeStance Health Group, Inc. has a one year low of $3.74 and a one year high of $8.30. The company’s 50 day moving average price is $5.95 and its 200 day moving average price is $5.37.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.03. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The company had revenue of $363.81 million during the quarter, compared to analyst estimates of $355.06 million. During the same quarter in the prior year, the business earned ($0.02) earnings per share. The business’s quarterly revenue was up 16.3% compared to the same quarter last year. On average, sell-side analysts predict that LifeStance Health Group, Inc. will post -0.18 EPS for the current year.

Institutional Trading of LifeStance Health Group

Institutional investors and hedge funds have recently made changes to their positions in the stock. Park Edge Advisors LLC bought a new stake in LifeStance Health Group in the second quarter valued at $52,000. Bayesian Capital Management LP bought a new stake in LifeStance Health Group in the 2nd quarter valued at about $52,000. Public Employees Retirement System of Ohio acquired a new position in LifeStance Health Group during the 2nd quarter valued at about $70,000. Blair William & Co. IL acquired a new position in LifeStance Health Group during the 2nd quarter valued at about $70,000. Finally, Vanguard Personalized Indexing Management LLC bought a new position in LifeStance Health Group in the 3rd quarter worth about $72,000. 85.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have commented on LFST shares. UBS Group boosted their price objective on LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. BTIG Research boosted their price target on LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Wall Street Zen cut LifeStance Health Group from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. BMO Capital Markets initiated coverage on shares of LifeStance Health Group in a research note on Thursday, November 13th. They set an “outperform” rating and a $8.00 price objective on the stock. Finally, Barclays assumed coverage on LifeStance Health Group in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $8.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $8.83.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.